Small Molecules
1 August 2017
Aptinyx Initiates Phase 2 Clinical Studies Evaluating NYX-2925 in Two Chronic Pain Conditions1 August 2017
Madrigal Pharmaceuticals Completes Enrollment in Phase 2 Proof-of-Concept Study with MGL-3196 for Treatment of NASH1 August 2017
Cycle Pharmaceuticals Receives FDA Approval of NityrTM (nitisinone) Tablets for Treatment of HT-11 August 2017
Proteostasis Therapeutics Announces Progression of PTI-428 and PTI-801 to Longer Duration Studies in CF Subjects31 July 2017
Pain Therapeutics Announces FDA Has Cleared an Investigational New Drug (IND) Application for PTI-12529 July 2017
ACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult and elderly patients with insomnia27 July 2017
NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports